MedPath

Prospective study on the clinical efficacy of Darolutamide in non-metastatic castration-resistant prostate cancer

Not Applicable
Recruiting
Conditions
non-metastatic prostate cancer
Registration Number
JPRN-UMIN000040914
Lead Sponsor
Department of Urology, Gunma University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
160
Inclusion Criteria

Not provided

Exclusion Criteria

1 Epileptic state patients 2 Brain damage, apoplexy, brain metastatis, active epidural metastatis of cranium 3 Hypersensitivity to darolutamide or its component 4 Severe liver dysfunction 5 Severe kidney function 6 Cases with distant metastases at the first visit 7 Impropriate state judged by charged doctor

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath